This menu provides the list of EV miRNAs identified by high-throughput analyses.

Search:
Superdomain: All Prokaryote Eukaryote
Filter datasets:
  - "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
  - "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
Maximum false positive rate (FPR): Maximum true positive rate (TPR):
  - FPR is the probability that an absent miRNA accidently have higher intensity than that miRNA.
  - TPR is the percentile of miRNA among the present miRNAs.
    Please see user manual in the contact us/help menu for detail.
Number of molecules in one page:

The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.

Since there are multiple primers in the microarray, the same miRNA can have several FPR and TPR values.

Mature name miRBase accession FPR TPR Publication Orthologous group Identification count
All / Prokaryote / Eukaryote
(FPR<0.05,TPR<0.5)
hsa-miR-490-3pMIMAT0002806 0.0e+0 4.8e-1Characterization of human plasma-derived exosomal RNAs by deep sequencing.
BMC Genomics. 2013 May 10;14:319. doi: 10.1186/1471-2164-14-319.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 0.0e+0 4.8e-1Characterization of human plasma-derived exosomal RNAs by deep sequencing.
BMC Genomics. 2013 May 10;14:319. doi: 10.1186/1471-2164-14-319.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 0.0e+0 4.8e-1Characterization of human plasma-derived exosomal RNAs by deep sequencing.
BMC Genomics. 2013 May 10;14:319. doi: 10.1186/1471-2164-14-319.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 1.3e-7 0.0e+0Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells.
J Biol Chem. 2013 Nov 29;288(48):34343-51. doi: 10.1074/jbc.M113.480822. Epub 2013 Oct 16.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 0.0e+0 5.7e-2Circulating exosomal microRNAs as biomarkers of colon cancer.
PLoS One. 2014 Apr 4;9(4):e92921. doi: 10.1371/journal.pone.0092921. eCollection 2014.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 5.5e-3 0.0e+0Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 3.8e-3 0.0e+0Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 9.7e-3 0.0e+0Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 9.3e-4 9.3e-4Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 1.1e-3 1.1e-3Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 6.6e-9 0.0e+0Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 1.1e-12 4.6e-1Combined Evaluation of a Panel of Protein and miRNA Serum Exosome Biomarkers for Pancreatic Cancer Diagnosis Increases Sensitivity and Specificity.
Int J Cancer. 2014 Nov 12. doi: 10.1002/ijc.29324.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 0.0e+0 1.7e-2Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis.
Cancer Cell. 2014 Nov 10;26(5):707-721. doi: 10.1016/j.ccell.2014.09.005. Epub 2014 Oct 23.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 0.0e+0 1.2e-2Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis.
Cancer Cell. 2014 Nov 10;26(5):707-721. doi: 10.1016/j.ccell.2014.09.005. Epub 2014 Oct 23.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 0.0e+0 5.2e-2Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis.
Cancer Cell. 2014 Nov 10;26(5):707-721. doi: 10.1016/j.ccell.2014.09.005. Epub 2014 Oct 23.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 0.0e+0 1.4e-1Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis.
Cancer Cell. 2014 Nov 10;26(5):707-721. doi: 10.1016/j.ccell.2014.09.005. Epub 2014 Oct 23.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 0.0e+0 1.4e-2Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis.
Cancer Cell. 2014 Nov 10;26(5):707-721. doi: 10.1016/j.ccell.2014.09.005. Epub 2014 Oct 23.
MIPF0000229_220 / 0 / 20
mmu-miR-490-3pMIMAT0003780 1.0e-3 1.0e-3Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue.
J Clin Invest. 2017 Apr 3;127(4):1375-1391. doi: 10.1172/JCI87993. Epub 2017 Mar 20.
MIPF0000229_220 / 0 / 20
rno-miR-490-3pMIMAT0012823 1.0e-3 1.0e-3Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue.
J Clin Invest. 2017 Apr 3;127(4):1375-1391. doi: 10.1172/JCI87993. Epub 2017 Mar 20.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 4.6e-5 0.0e+0Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.
MIPF0000229_220 / 0 / 20
hsa-miR-490-3pMIMAT0002806 1.8e-2 1.8e-2Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.
MIPF0000229_220 / 0 / 20
[1]